CN102212124B - 拟穴青蟹抗脂多糖因子及其制备方法与应用 - Google Patents
拟穴青蟹抗脂多糖因子及其制备方法与应用 Download PDFInfo
- Publication number
- CN102212124B CN102212124B CN2011101273799A CN201110127379A CN102212124B CN 102212124 B CN102212124 B CN 102212124B CN 2011101273799 A CN2011101273799 A CN 2011101273799A CN 201110127379 A CN201110127379 A CN 201110127379A CN 102212124 B CN102212124 B CN 102212124B
- Authority
- CN
- China
- Prior art keywords
- scylla
- lipopolysaccharide factor
- lipopolysaccharide
- preparation
- factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 241001672730 Scylla paramamosain Species 0.000 title description 5
- 241000238102 Scylla Species 0.000 claims abstract description 19
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 16
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 16
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 14
- 239000013604 expression vector Substances 0.000 claims abstract description 12
- 238000003259 recombinant expression Methods 0.000 claims abstract description 11
- 241000186226 Corynebacterium glutamicum Species 0.000 claims abstract description 7
- 241000589540 Pseudomonas fluorescens Species 0.000 claims abstract description 7
- 241000589614 Pseudomonas stutzeri Species 0.000 claims abstract description 6
- 241000607762 Shigella flexneri Species 0.000 claims abstract description 6
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 239000000654 additive Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- 229940079593 drug Drugs 0.000 claims abstract description 3
- 230000001939 inductive effect Effects 0.000 claims abstract description 3
- 230000003385 bacteriostatic effect Effects 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 14
- 241000235058 Komagataella pastoris Species 0.000 claims description 7
- 238000000746 purification Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 claims description 2
- OVVUNXXROOFSIM-SDDRHHMPSA-N Arg-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O OVVUNXXROOFSIM-SDDRHHMPSA-N 0.000 claims description 2
- DNLQVHBBMPZUGJ-BQBZGAKWSA-N Arg-Ser-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O DNLQVHBBMPZUGJ-BQBZGAKWSA-N 0.000 claims description 2
- DDBMKOCQWNFDBH-RHYQMDGZSA-N Arg-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)O DDBMKOCQWNFDBH-RHYQMDGZSA-N 0.000 claims description 2
- NCXTYSVDWLAQGZ-ZKWXMUAHSA-N Asn-Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O NCXTYSVDWLAQGZ-ZKWXMUAHSA-N 0.000 claims description 2
- KVMPVNGOKHTUHZ-GCJQMDKQSA-N Asp-Ala-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KVMPVNGOKHTUHZ-GCJQMDKQSA-N 0.000 claims description 2
- LIQNMKIBMPEOOP-IHRRRGAJSA-N Asp-Phe-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CC(=O)O)N LIQNMKIBMPEOOP-IHRRRGAJSA-N 0.000 claims description 2
- XIZWKXATMJODQW-KKUMJFAQSA-N Cys-His-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CC2=CN=CN2)NC(=O)[C@H](CS)N XIZWKXATMJODQW-KKUMJFAQSA-N 0.000 claims description 2
- WIMVKDYAKRAUCG-IHRRRGAJSA-N Gln-Tyr-Glu Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WIMVKDYAKRAUCG-IHRRRGAJSA-N 0.000 claims description 2
- RLZBLVSJDFHDBL-KBIXCLLPSA-N Glu-Ala-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O RLZBLVSJDFHDBL-KBIXCLLPSA-N 0.000 claims description 2
- KRGZZKWSBGPLKL-IUCAKERBSA-N Glu-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)N KRGZZKWSBGPLKL-IUCAKERBSA-N 0.000 claims description 2
- GWCRIHNSVMOBEQ-BQBZGAKWSA-N Gly-Arg-Ser Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O GWCRIHNSVMOBEQ-BQBZGAKWSA-N 0.000 claims description 2
- QSVMIMFAAZPCAQ-PMVVWTBXSA-N Gly-His-Thr Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QSVMIMFAAZPCAQ-PMVVWTBXSA-N 0.000 claims description 2
- LRQXRHGQEVWGPV-NHCYSSNCSA-N Gly-Leu-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN LRQXRHGQEVWGPV-NHCYSSNCSA-N 0.000 claims description 2
- FBUMPXILDTWCJW-UHFFFAOYSA-N Gly-Trp-Ala-Pro Natural products C=1NC2=CC=CC=C2C=1CC(NC(=O)CN)C(=O)NC(C)C(=O)N1CCCC1C(O)=O FBUMPXILDTWCJW-UHFFFAOYSA-N 0.000 claims description 2
- DLCXCECTCPKKCD-GUBZILKMSA-N Leu-Gln-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O DLCXCECTCPKKCD-GUBZILKMSA-N 0.000 claims description 2
- APFJUBGRZGMQFF-QWRGUYRKSA-N Leu-Gly-Lys Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN APFJUBGRZGMQFF-QWRGUYRKSA-N 0.000 claims description 2
- VDIARPPNADFEAV-WEDXCCLWSA-N Leu-Thr-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O VDIARPPNADFEAV-WEDXCCLWSA-N 0.000 claims description 2
- OZTZJMUZVAVJGY-BZSNNMDCSA-N Leu-Tyr-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N OZTZJMUZVAVJGY-BZSNNMDCSA-N 0.000 claims description 2
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 claims description 2
- AZOFEHCPMBRNFD-BZSNNMDCSA-N Lys-Phe-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CC=CC=C1 AZOFEHCPMBRNFD-BZSNNMDCSA-N 0.000 claims description 2
- OHXUUQDOBQKSNB-AVGNSLFASA-N Lys-Val-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OHXUUQDOBQKSNB-AVGNSLFASA-N 0.000 claims description 2
- JIWJRKNYLSHONY-KKUMJFAQSA-N Pro-Phe-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O JIWJRKNYLSHONY-KKUMJFAQSA-N 0.000 claims description 2
- KQNDIKOYWZTZIX-FXQIFTODSA-N Ser-Ser-Arg Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCNC(N)=N KQNDIKOYWZTZIX-FXQIFTODSA-N 0.000 claims description 2
- ZQUKYJOKQBRBCS-GLLZPBPUSA-N Thr-Gln-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O ZQUKYJOKQBRBCS-GLLZPBPUSA-N 0.000 claims description 2
- FLPZMPOZGYPBEN-PPCPHDFISA-N Thr-Leu-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FLPZMPOZGYPBEN-PPCPHDFISA-N 0.000 claims description 2
- XKKBFNPJFZLTMY-CWRNSKLLSA-N Trp-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CC2=CNC3=CC=CC=C32)N)C(=O)O XKKBFNPJFZLTMY-CWRNSKLLSA-N 0.000 claims description 2
- AWEGFIJXYWGBCA-XIRDDKMYSA-N Trp-His-Asn Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CN=CN3)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AWEGFIJXYWGBCA-XIRDDKMYSA-N 0.000 claims description 2
- PAPWZOJOLKZEFR-AVGNSLFASA-N Val-Arg-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(=O)O)N PAPWZOJOLKZEFR-AVGNSLFASA-N 0.000 claims description 2
- KJFBXCFOPAKPTM-BZSNNMDCSA-N Val-Trp-Val Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 KJFBXCFOPAKPTM-BZSNNMDCSA-N 0.000 claims description 2
- 241000607598 Vibrio Species 0.000 claims description 2
- 150000001413 amino acids Chemical group 0.000 claims description 2
- 108010013835 arginine glutamate Proteins 0.000 claims description 2
- 108010062796 arginyllysine Proteins 0.000 claims description 2
- 108010005942 methionylglycine Proteins 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 108700004896 tripeptide FEG Proteins 0.000 claims description 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 241000238095 Scylla serrata Species 0.000 abstract description 9
- 239000002158 endotoxin Substances 0.000 abstract description 9
- 229920006008 lipopolysaccharide Polymers 0.000 abstract description 8
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 241000607594 Vibrio alginolyticus Species 0.000 abstract description 3
- 230000009422 growth inhibiting effect Effects 0.000 abstract description 3
- 239000000047 product Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000001962 electrophoresis Methods 0.000 description 8
- 241001506991 Komagataella phaffii GS115 Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 5
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 5
- 241000239218 Limulus Species 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 244000000010 microbial pathogen Species 0.000 description 5
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 4
- 241000238557 Decapoda Species 0.000 description 4
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 241000193755 Bacillus cereus Species 0.000 description 2
- 241000238424 Crustacea Species 0.000 description 2
- 241000371997 Eriocheir sinensis Species 0.000 description 2
- 241000238553 Litopenaeus vannamei Species 0.000 description 2
- 241001124325 Marsupenaeus japonicus Species 0.000 description 2
- 241001533364 Portunus trituberculatus Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000019730 animal feed additive Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 241000238097 Callinectes sapidus Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000995704 Fenneropenaeus chinensis Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000241034 Palaemon pugio Species 0.000 description 1
- 241000927735 Penaeus Species 0.000 description 1
- 241000238552 Penaeus monodon Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 241000238147 Portunidae Species 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 108091001629 crustin Proteins 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000012897 dilution medium Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
拟穴青蟹抗脂多糖因子及其制备方法与应用。涉及拟穴青蟹基因工程,提供拟穴青蟹抗脂多糖因子及其制备方法与应用。制备方法包括以下步骤:构建拟穴青蟹抗脂多糖因子重组表达载体;将所得重组表达载体导入宿主细胞,并将宿主细胞进行诱导表达,获得表达产物;分离纯化步所得的表达产物,获得重组蛋白,即拟穴青蟹抗脂多糖因子。拟穴青蟹抗脂多糖因子对革兰氏阴性菌弗氏志贺氏菌、解藻朊酸弧菌、副溶血性弧菌、施氏假单胞菌和荧光假单胞菌,革兰氏阳性菌谷氨酸棒杆菌具有明显抑制生长作用和杀菌作用,在制备抑菌药和作为动物饲料抗菌添加剂中具有潜在的应用价值。
Description
技术领域
本发明涉及拟穴青蟹基因工程,特别涉及拟穴青蟹抗脂多糖因子及其制备方法与应用。
背景技术
拟穴青蟹(Scylla paramamosain)属于梭子蟹科(Portunidae)暖水广盐性海洋蟹类,在中国大陆东南沿海分布最广,数量最多。随着拟穴青蟹集中养殖规模地不断扩大,由细菌、真菌和病毒等因素引起的疾病对蟹类养殖业带来巨大损失。众所周知,甲壳类动物主要依靠先天性免疫系统来抵御外界病原微生物,多种先天性免疫因子参与其抗感染过程,包括凝集素(agglutinin)、溶血素(hemolysin)、溶菌酶(1ysozeme)、酚氧化酶(phenoloxidase)系统、蛋白酶抑制剂、抗菌肽(antimicrobial peptide,AMP)等。
抗脂多糖因子(Anti-lipopolysaccharide factor,ALF)是最初发现于鲎(1.TanakaS,Nakamura T,Morita T,Iwanaga S.Limulus anti-LPS factor:an anticoagulant which inhibits theendotoxin mediated activation of Limulus coagulation system[J].Biochem Biophys Res Commun,1982,105(2):717-723)体内的一种抗菌肽,与细胞内毒素(脂多糖,LPS)具有高亲和力,已证明它具有结合LPS的类脂A部位并能够在体外中和LPS的生物学活性,通过一些动物模型的体内研究,发现鲎抗脂多糖因子(LALF)和其环肽部分(LALF31-52,LALF35-52)在内毒素血症和对抗内毒素休克的效用。随后的研究也表明,鲎抗脂多糖因子(LALF)对R-型革兰氏阴性菌生长具有强烈的抑制作用,故认为LALF具有免疫调控功能,并对鲎抵御病原微生物感染具有重要意义。近年来,研究者们陆续从中国明对虾(2.Liu F,Liu Y,Li F,DongB,Xiang J.Molecular cloning and expression profile of putative antilipopolysaccharide factor inChinese shrimp(Fenneropenaeus chinensis)[J]Mar Biotechnol(NY),2005,7(6):600-608)、南美白对虾(3.Vega Edl,O’Leary NA,Shockey JE,Robalino J,Payne C,Browdy CL,Warr GW,Gross PS.Anti-lipopolysaccharide factor in Litopenaeus vannamei(LvALF):a broad spectrumantimicrobial peptide essential for shrimp immunity against bacterial and fungal infection[J].MolImmunol,2008,45(7):1916-1925)、草虾(4.Somboonwiwat K,Marcos M,Tassanakajon A,Klinbunga S,Aumelas A,Romestand B,Gueguen Y,Boze H,Moulin G,Bachere E.Recombinantexpression and anti-microbial activity of anti-lipopolysaccharide factor(ALF)from the black tigershrimp Penaeus monodon[J].Dev Comp Immunol,2005,29(10):841-851)、三疣梭子蟹(5.Yue F,Pan L,Miao J,Zhang L,Li J.Molecular cloning,characterization and mRNA expression of twoantibacterial peptides:Crustin and anti-lipopolysaccharide factor in swimming crab Portunustrituberculatus[J].Comparative Biochemistry and Physiology Part B:Biochemistry and MolecularBiology,2010,156(2):77-85.)、中华绒螯蟹(6.Li C,Zhao J,Song L,Mu C,Zhang H,Gai Y,QiuL,Yu Y,Ni D,Xing K.Molecular cloning,genomic organization and functional analysis of ananti-lipopolysaccharide factor from Chinese mitten crab Eriocheir sinensis[J].Dev Comp Immunol,2008,32(7):784-794.)、锯缘青蟹(7.Yedery RD,Reddy KV.Identification,cloning,characterization and recombinant expression of an anti-lipopolysaccharide factor from thehemocytes of Indian mud crab,Scylla serrata[J].Fish Shellfish Immunol,2009,27(2):275-284.)、日本囊对虾(8.Mekata T,Sudhakaran R,Okugawa S,Kono T,Sakai M,Itami T.Molecular cloningand transcriptional analysis of a newly identified anti-lipopolysaccharide factor gene in kurumashrimp,Marsupenaeus japonicus[J]Lett Appl Microbiol,2010,50(1):112-119.)等其他甲壳动物分离鉴定了抗脂多糖因子。
发明内容
本发明的目的在于提供拟穴青蟹抗脂多糖因子及其制备方法与应用。
根据拟穴青蟹(Scylla paramamosain)和抗脂多糖因子(Anti-lipopolysaccharide factor,ALF)可将拟穴青蟹抗脂多糖因子简写为Sp-ALF。
所述拟穴青蟹抗脂多糖因子的基因序列为:
cagtatgaaa ctctgatagc ctccgttctt ggaaaactca ctggactgtg gcacaacaac 60
tcagtggact tcatgggcca cacctgtcac ttccgccgcc gtcctaaggt caggaaattc 120
aagctgtacc acgagggcaa gttttggtgt cctggctggg cgccttttga gggcaggtcg 180
aggacaaaga gcaggtcggg gtcatccagg gaagccatca aggacttcgt gcgcaaagct 240
ttacagaacg gactcatcac acagcaggac gctacggtgt gggtgaataa t 291
所述拟穴青蟹抗脂多糖因子的氨基酸序列为:
Gln Tyr Glu Thr Leu Ile Ala Ser Val Leu Gly Lys Leu Thr Gly Leu
1 5 10 15
Trp His Asn Asn Ser Val Asp Phe Met Gly His Thr Cys His Phe Arg
20 25 30
Arg Arg Pro Lys Val Arg Lys Phe Lys Leu Tyr His Glu Gly Lys Phe
35 40 45
Trp Cys Pro Gly Trp Ala Pro Phe Glu Gly Arg Ser Arg Thr Lys Ser
50 55 60
Arg Ser Gly Ser Ser Arg Glu Ala Ile Lys Asp Phe Val Arg Lys Ala
65 70 75 80
Leu Gln Asn Gly Leu Ile Thr Gln Gln Asp Ala Thr Val Trp Val Asn
85 90 95
Asn
所述拟穴青蟹抗脂多糖因子的制备方法包括以下步骤:
1)构建拟穴青蟹抗脂多糖因子重组表达载体;
2)将步骤1)所得重组表达载体导入宿主细胞,并将宿主细胞进行诱导表达,获得表达产物;
3)分离纯化步骤2)所得的表达产物,获得重组蛋白,即拟穴青蟹抗脂多糖因子。
在步骤1)中,所述表达载体可选用pPIC9k等。
在步骤2)中,所述宿主细胞可为毕赤酵母等。
在步骤3)中,所述分离纯化可为先将表达产物进行透析,再进行亲和层析。
所述拟穴青蟹抗脂多糖因子对革兰氏阴性菌弗氏志贺氏菌、解藻朊酸弧菌、副溶血性弧菌、施氏假单胞菌和荧光假单胞菌,革兰氏阳性菌谷氨酸棒杆菌具有明显抑制生长作用和杀菌作用,在制备抑菌新药和作为动物饲料抗菌添加剂中具有潜在的应用价值。
本发明分离出拟穴青蟹抗脂多糖因子Sp-ALF的基础上,根据Sp-ALF基因序列特征成功构建重组表达载体并在毕赤酵母系统中表达并纯化获得Sp-ALF蛋白,该重组蛋白具有广谱的抗菌活性,表明Sp-ALF可能广泛参与了拟穴青蟹抗微生物感染的先天免疫反应,重组蛋白在动物饲料添加剂和抗病原微生物新药物开发上显示出诱人的应用前景。
附图说明
图1为pPIC9k载体双酶切前后电泳图谱。1为酶切前的pPIC9k载体;2为酶切后pPIC9k载体,bp为碱基,2000为分子量;M为DS2000DNA Marker。
图2为表达载体pPIC9k、pPIC9k/Sp-ALF1和pPIC9k/Sp-ALF2Sal I线性化前后电泳图谱。1为pPIC9k,2为酶切后pPIC9k,3为pPIC9k/Sp-ALF,4为酶切后的pPIC9k/Sp-ALF,M为DS2000DNA Marker,bp为碱基,2000为分子量。
图3为pPIC9k/Sp-ALF重组毕赤酵母克隆子甲醇诱导表达检测SDS-PAGE电泳图谱。1为诱导前表达情况;2~4分别为甲醇诱导12h、24h、48h的表达产物;M为SDS-PAGE标准蛋白质Marker,18和14为电泳的重组蛋白Sp-ALF。
图4为pPIC9k/Sp-ALF重组毕赤酵母甲醇诱导表达产物纯化检测电泳图谱。1:上样前产物;2~3:穿过峰的产物;4~8:溶液D洗脱峰的产物;M:SDS-PAGE标准蛋白质Marker,18和14为电泳的重组蛋白Sp-ALF。
具体实施方式
以下通过实施例结合附图详细说明本发明的技术方案。
实施例1拟穴青蟹抗脂多糖因子Sp-ALF真核重组表达载体的构建
根据pPIC9k载体多克隆位点,设计扩增编码拟穴青蟹Sp-ALF(cDNA)基因ORF的特异性上游引物F1和下游引物R1。在上游引物F1的5′端添加SnaB I酶切位点和编码His-tag的碱基;在下游引物R1的5′端添加终止密码子和Avr II酶切位点:
上游引物F1:5′-CGTACGTACACCATCATCATCATCATCAGTATGAAACTCTGATAG-3′,
下游引物R1:5′-AA CCTAGGTTAATTATTCACCCACACCGTAG-3′。
扩增Sp-ALF的编码区片段。PCR反应条件为:94℃预变性5min;94℃变性30s,60℃退火30s,72℃延伸30s,重复30个循环;72℃延伸10min。
将PCR产物进行琼脂糖凝胶纯化试剂盒回收,回收的PCR产物用SnaB I和Avr II进行酶切后纯化回收,与用SnaB I和Avr II双酶切线性化pPIC9k载体连接,构建好酵母表达重组载体pPIC9k/Sp-ALF,点样进行电泳检测(参见图1)。
实施例2pPIC9k/Sp-ALF重组质粒在毕赤酵母GS 115中的诱导表达
用Sal I对测序正确的质粒pPIC9k/Sp-ALF进行酶切线性化(参见图2),再将其用电击法转化至毕赤酵母GS115感受态细胞中,并诱导表达。
以pPIC9k空质粒转化的毕赤酵母GS115为对照,以pPIC9k/Sp-ALF重组质粒转化的毕赤酵母GS115为实验组,利用聚丙烯酰胺凝胶电泳(SDS-PAGE)检测蛋白的表达。
结果显示,以pPIC9k/Sp-ALF重组质粒转化的毕赤酵母GS115在经过诱导后与诱导前相比具有明显的蛋白质诱导表达,蛋白条带在14kDa左右(参见图3),与计算的理论分子量相似,另外重组子的诱导表达产物中还有一条18kDa左右大小的条带,经质谱鉴定后亦为Sp-ALF,推测是表达分泌过程中可能发生潜在的糖基化修饰。
实施例3pPIC9k/Sp-ALF重组质粒在毕赤酵母GS115中诱导表达产物的纯化及抗菌活性鉴定
1、亲和层析法纯化目的蛋白
将重组阳性毕赤酵母GS115菌株大量诱导表达后,离心去除菌体收集培养基上清1L,PBS透析两次(12h换一次新透析液)后,4℃,12000rpm离心35min,取上清,得到上柱样品。接着采用金属鏊合层析柱对透析后的蛋白进行亲和层析。收集洗脱峰,经SDS-PAGE电泳分析及质谱鉴定为Sp-ALF重组蛋白(参见图4)。
2、Sp-ALF重组蛋白抗菌活性鉴定
应用Bradford法测定BSA标准品得到蛋白浓度标准曲线。根据公式可计算出Sp-ALF重组蛋白的浓度。
Sp-ALF重组蛋白抗菌活性的测定:目的蛋白的稀释按照最低抑菌浓度(MIC)设定浓度进行,用μM为单位进行稀释配比,如25、12.5、6.25、3.12和1.6μM为梯度在96孔微量培养板上进行。蛋白样品要经过0.22μm过滤膜过滤除菌菌再进行稀释配比,每个浓度设置一个平行孔。取被测细菌,在MH或2216平板上划线,倒置培养12~16h;挑取单克隆接种于MH或2216斜面,继续培养过夜达到中期对数生长阶段;用DPBS(1.58mM NaH2PO4,8.42mMNa2HPO4,pH 7.2~7.4)清洗斜面培养物,调整稀释至OD600=0.1,取18μl OD600=0.1的稀释菌加入终体积为1ml的MH稀释培养基(DPBS:600μl,MH:400μl)中,该菌浓度则为MIC工作浓度。其中大肠杆菌模式株、谷氨酸棒杆菌、金黄色葡萄球菌、蜡状芽孢杆菌和弗氏志贺氏菌培养温度为37℃,副溶血性弧菌、解藻朊酸弧菌、荧光假单胞菌和施氏假单胞菌培养温度为28℃。
MIC在96孔细胞培养板上进行,每种被测细菌按照以下操作设置空白对照组、阴性对照组和待测样品实验组,每组设置2个平行样,加样体系分别为:
①空白对照组:加50μl蛋白样品和50μl DPBS;
②阴性对照组:加50μl菌悬液和50μl DPBS;
③样品实验组:加50μ1待测各浓度蛋白样品和50μ1菌悬液。
28℃培养24h后,判定Sp-ALF重组蛋白对细菌的MIC(Minimum Inhibitory Concentration,最低抑菌浓度),判定标准为该浓度细菌数少于或等于对照(未添加抗菌肽)中的一半。
利用测定最小抑菌浓度(MIC)以上各孔培养物,分别吸取5μl,移种在琼脂培养基上,经孵育过夜,判定Sp-ALF重组蛋白对细菌的MBC(Minimum Bactericidal Concentration,最低杀菌浓度),即杀死某种菌株的药物最低浓度。
结果显示,真核表达的Sp-ALF蛋白产物能够对受试菌:大肠杆菌模式株、弗氏志贺氏菌、副溶血性弧菌、解藻朊酸弧菌、施氏假单胞菌、荧光假单胞菌,谷氨酸棒杆菌、金黄色葡萄球菌和蜡状芽孢杆菌(均购自中国科学院微生物研究所菌种保藏中心)均具有较强杀伤作用(参见表1)。
表1
a:MIC(Minimum Inhibitory Concentration,最低抑菌浓度)
b::MBC(Minimum Bactericidal Concentration,最低杀菌浓度)
本发明旨在获得拟穴青蟹Sp-ALF基因工程表达产品,并对其抗微生物活性进行鉴定,以期开发抗病原微生物的新药物。本发明获得了拟穴青蟹Sp-ALF基因工程表达重组子pPIC9k/Sp-ALF,并在毕赤酵母成功重组表达获得Sp-ALF基因工程产品,确认了Sp-ALF的广谱性抗菌活性,为其作为动物饲料添加剂和抗病原微生物新药物的开发奠定了基础。
本发明根据拟穴青蟹抗脂多糖因子Sp-ALF基因序列特征,构建真核重组表达载体、转化毕赤酵母诱导表达并纯化获得Sp-ALF重组蛋白,鉴定重组蛋白抗微生物活性,研究发现Sp-ALF重组蛋白具有高效抗微生物活性:对革兰氏阴性菌弗氏志贺氏菌、解藻朊酸弧菌、副溶血性弧菌、施氏假单胞菌和荧光假单胞菌,革兰氏阳性菌谷氨酸棒杆菌具有明显抑制生长作用和杀菌作用。
Claims (7)
1.拟穴青蟹抗脂多糖因子,其特征在于所述拟穴青蟹抗脂多糖因子的基因序列为:
cagtatgaaa ctctgatagc ctccgttctt ggaaaactca ctggactgtg gcacaacaac 60
tcagtggact tcatgggcca cacctgtcac ttccgccgcc gtcctaaggt caggaaattc 120
aagctgtacc acgagggcaa gttttggtgt cctggctggg cgccttttga gggcaggtcg 180
aggacaaaga gcaggtcggg gtcatccagg gaagccatca aggacttcgt gcgcaaagct 240
ttacagaacg gactcatcac acagcaggac gctacggtgt gggtgaataa t 291。
2.如权利要求1所述的拟穴青蟹抗脂多糖因子,其特征在于所述拟穴青蟹抗脂多糖因子的氨基酸序列为:
Gln Tyr Glu Thr Leu Ile Ala Ser Val Leu Gly Lys Leu Thr Gly Leu
1 5 10 15
Trp His Asn Asn Ser Val Asp Phe Met Gly His Thr Cys His Phe Arg
20 25 30
Arg Arg Pro Lys Val Arg Lys Phe Lys Leu Tyr His Glu Gly Lys Phe
35 40 45
Trp Cys Pro Gly Trp Ala Pro Phe Glu Gly Arg Ser Arg Thr Lys Ser
50 55 60
Arg Ser Gly Ser Ser Arg Glu Ala Ile Lys Asp Phe Val Arg Lys Ala
65 70 75 80
Leu Gln Asn Gly Leu Ile Thr Gln Gln Asp Ala Thr Val Trp Val Asn
85 90 95
Asn。
3.如权利要求1所述的拟穴青蟹抗脂多糖因子的制备方法,其特征在于包括以下步骤:
1)构建拟穴青蟹抗脂多糖因子重组表达载体,所述表达载体选用pPIC9k;
2)将步骤1)所得重组表达载体导入宿主细胞,并将宿主细胞进行诱导表达,获得表达产物;
3)分离纯化步骤2)所得的表达产物,获得重组蛋白,即拟穴青蟹抗脂多糖因子。
4.如权利要求3所述的拟穴青蟹抗脂多糖因子的制备方法,其特征在于在步骤2)中,所述宿主细胞为毕赤酵母。
5.如权利要求3所述的拟穴青蟹抗脂多糖因子的制备方法,其特征在于在步骤3)中,所述分离纯化为先将表达产物进行透析,再进行亲和层析。
6.如权利要求1所述的拟穴青蟹抗脂多糖因子在制备抑菌药中的应用,所述菌为革兰氏阴性菌-大肠杆菌、弗氏志贺氏菌、解藻朊酸弧菌、副溶血性弧菌、施氏假单胞菌、荧光假单胞菌或抗革兰氏阳性菌-谷氨酸棒杆菌。
7.如权利要求1所述的拟穴青蟹抗脂多糖因子在制备动物饲料抗菌添加剂中的应用,所述菌为革兰氏阴性菌-大肠杆菌、弗氏志贺氏菌、解藻朊酸弧菌、副溶血性弧菌、施氏假单胞菌、荧光假单胞菌或抗革兰氏阳性菌-谷氨酸棒杆菌。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101273799A CN102212124B (zh) | 2011-05-17 | 2011-05-17 | 拟穴青蟹抗脂多糖因子及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011101273799A CN102212124B (zh) | 2011-05-17 | 2011-05-17 | 拟穴青蟹抗脂多糖因子及其制备方法与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102212124A CN102212124A (zh) | 2011-10-12 |
CN102212124B true CN102212124B (zh) | 2012-07-18 |
Family
ID=44743688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011101273799A Expired - Fee Related CN102212124B (zh) | 2011-05-17 | 2011-05-17 | 拟穴青蟹抗脂多糖因子及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102212124B (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102352363B (zh) * | 2011-10-25 | 2013-07-24 | 厦门大学 | 拟穴青蟹抗病毒型抗脂多糖因子及其制备方法与应用 |
CN103601795A (zh) * | 2013-11-08 | 2014-02-26 | 中国水产科学研究院东海水产研究所 | 拟穴青蟹抗真菌型抗脂多糖因子及其制备方法和应用 |
CN105219779B (zh) * | 2015-11-12 | 2018-06-15 | 厦门大学 | 红螯螯虾抗脂多糖因子及其制备方法与应用 |
CN105255750A (zh) * | 2015-11-17 | 2016-01-20 | 江南大学 | 一种高效表达中华绒螯蟹抗脂多糖因子的酿酒酵母工程菌 |
CN105688669B (zh) * | 2016-03-08 | 2018-03-09 | 江苏可兰素汽车环保科技有限公司 | 梳状聚丙烯酰胺类晶体增长干扰剂、利用该干扰剂制备的抗结晶型尾气催化还原剂及制法 |
CN106699862B (zh) * | 2016-11-22 | 2020-06-09 | 中国科学院海洋研究所 | 三种来源于脊尾白虾alf的环状多肽及其应用和抗菌剂 |
CN106928333B (zh) * | 2017-02-15 | 2020-09-18 | 中国水产科学研究院东海水产研究所 | 一种拟穴青蟹抗病因子SpALF6单核苷酸突变体及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101230356A (zh) * | 2008-02-20 | 2008-07-30 | 厦门大学 | 拟穴青蟹蛋白二硫键异构酶保守区域cDNA序列及其克隆方法 |
WO2009021468A1 (es) * | 2007-07-31 | 2009-02-19 | Centro De Ingenieria Genetica Y Biotecnologia | Péptidos penetradores a células y su uso fusionados a biomoléculas con acción terapéutica |
CN101914149A (zh) * | 2010-01-16 | 2010-12-15 | 中国科学院海洋研究所 | 一种具有抑菌活性的抗脂多糖因子的制备及应用 |
-
2011
- 2011-05-17 CN CN2011101273799A patent/CN102212124B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009021468A1 (es) * | 2007-07-31 | 2009-02-19 | Centro De Ingenieria Genetica Y Biotecnologia | Péptidos penetradores a células y su uso fusionados a biomoléculas con acción terapéutica |
CN101230356A (zh) * | 2008-02-20 | 2008-07-30 | 厦门大学 | 拟穴青蟹蛋白二硫键异构酶保守区域cDNA序列及其克隆方法 |
CN101914149A (zh) * | 2010-01-16 | 2010-12-15 | 中国科学院海洋研究所 | 一种具有抑菌活性的抗脂多糖因子的制备及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN102212124A (zh) | 2011-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102212124B (zh) | 拟穴青蟹抗脂多糖因子及其制备方法与应用 | |
Sun et al. | An anti-lipopolysaccharide factor from red swamp crayfish, Procambarus clarkii, exhibited antimicrobial activities in vitro and in vivo | |
CN102863539B (zh) | 融合串联抗菌肽及其制备方法 | |
CN104151414B (zh) | 拟穴青蟹抗菌肽SpHyastatin的制备方法与应用 | |
CN105219779B (zh) | 红螯螯虾抗脂多糖因子及其制备方法与应用 | |
CN111420037A (zh) | 噬菌体裂解酶Lysep3在制备广谱抗菌药物中的应用 | |
Neshani et al. | Preparation and evaluation of a new biopesticide solution candidate for plant disease control using pexiganan gene and Pichia pastoris expression system | |
CN102304516A (zh) | 拟穴青蟹阴离子抗菌肽的毕赤酵母表达产物及其制备方法 | |
CN102304536A (zh) | 两种海洋动物抗菌肽基因的真核融合表达产物及制备方法 | |
CN102352363A (zh) | 拟穴青蟹抗病毒型抗脂多糖因子及其制备方法与应用 | |
CN115894715A (zh) | 一种抗奶牛乳房炎主要致病菌的融合抗菌肽的制备 | |
CN104263709A (zh) | 鸡蛋清溶菌酶及其制备方法 | |
CN108148123B (zh) | 烧土火丝菌天然抗菌肽及其应用 | |
CN101319216A (zh) | 重组家蚕抗菌肽cm4的生产和纯化方法 | |
CN102242128A (zh) | 拟穴青蟹抗病毒型抗脂多糖因子及其制备方法与应用 | |
CN103333912A (zh) | 在Pichia pastoris中组成型表达菌丝霉素衍生物MP1102的方法 | |
CN103724412A (zh) | 中国明对虾抗脂多糖因子及其制备和应用 | |
CN108003233A (zh) | 长牡蛎含DM9结构域蛋白CgDM9CP-2、制备方法及应用 | |
CN103387992A (zh) | 编码重组猪β-防御素-1的基因及猪β-防御素-1的制备方法 | |
CN100485036C (zh) | 一种中国明对虾抗菌蛋白基因及重组表达和应用 | |
CN102020709A (zh) | 一种厚壳贻贝抗菌肽及制备方法和用途 | |
CN102433341B (zh) | 一种斜带石斑鱼抗菌肽的原核表达产物及其制备方法 | |
CN108752431A (zh) | 杂合抗菌肽Mel-MytB及其应用 | |
CN116196393A (zh) | 抗菌肽ap138在制备抗菌药物中的应用 | |
CN104447976A (zh) | 一种猪源抗菌肽cecropin P1突变体及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120718 Termination date: 20180517 |